16 October 2012 08:13 [Source: ICIS news]
SINGAPORE (ICIS)--Swiss pharmaceuticals firm Roche said on Tuesday its total sales rose by 7% year on year to Swiss franc (Swfr) 33.7bn ($36.2bn) in January-September 2012 on the back of strong demand for its cancer medicines and its clinical lab business.
On a constant exchange-rate basis, its sales rose by 4% year on year in the first nine months of this year, Roche said in a statement.
“Group sales were strong in the ?xml:namespace>
“The weakening of the Swiss franc against the dollar and the Japanese yen, particularly in the third quarter, supported the sales performance in Swiss franc terms,” the company said.
For the full year of 2012, Roche projects a low-to-mid single-digit sales growth at constant exchange rates for the group and its pharmaceuticals division.
Sales by the firm’s diagnostics division is expected to again outpace the market for the full year, it added.
($1 = Swfr0.93)
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
Asian Chemical Connections